Table 2 Univariate and multivariate analysis of PFS of all patients receiving ICI plus chemotherapy

Age(year) (< = 63.5/ > 63.5)

1.119

0.573–2.186

0.741

Sex (male/female)

1.068

0.558–2.043

0.843

Smoking(never/ever)

1.518

0.462–4.987

0.491

Histology(adeno/NOS)

0.955

0.333–2.741

0.932

Number of distant metastases

 0–1/ > 3

0.097

0.024–0.397

0.001

 2–3/ > 3

0.171

0.042–0.691

0.013

Bone metastasis(no/yes)

0.905

0.468–1.748

0.766

Brain metastasis(no/yes)

0.611

0.273–1.368

0.231

Liver metastasis(no/yes)

0.096

0.028–0.333

 < 0.001

0.060

0.016–0.226

 < 0.001

EGFR mutation

 L858R/19DEL

0.736

0.376–1.441

0.372

 G719X/19DEL

0.964

0.284–3.279

0.953

Acquired T790M(no/yes)

0.614

0.268–1.410

0.250

Other treatment(no/yes)

0.426

0.209–0.868

0.019

ICI line(2–3/ >  = 4)

0.273

0.123–0.603

0.001

Lymphocyte(< = 1.07/ > 1.07)

2.745

1.312–5.746

0.007

Neutrophile(< = 3.5/ > 3.5)

1.263

0.621–2.570

0.519

Eosinophils(< = 0.16/ > 0.16)

1.454

0.732–2.887

0.286

Platelet(< = 215/ > 215)

0.647

0.340–1.229

0.183

PLR(< = 200/ > 200)

0.335

0.133–0.842

0.020

0.229

0.085–0.616

0.003

NLR(< = 4/ > 4)

0.492

0.239–1.014

0.055